SynthesisBiomedica : revista del Instituto Nacional de Salud2026
Omadacycline for community-acquired infections: A systematic review and single-arm meta-analysis
Synthesis in Biomedica : revista del Instituto Nacional de Salud, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction. Community-acquired infections have a significant burden on healthcare systems and are caused by a variety of pathogens with different severities. Increasing microbial resistance complicates treatment, highlighting the need for new therapies. Omadacycline, a novel antibiotic, has broad-spectrum activity against both Gram-positive and Gram-negative pathogens, particularly those involved in community-acquired infections.Objective. To evaluate omadacycline’s efficacy and safety for treating community-acquired infections.Materials and methods. We searched PubMed, Embase, and Cochrane for randomized and non-randomized studies about omadacycline for community-acquired infections, with no time restrictions. Primary outcomes were clinical success at the end of treatment and post-treatment evaluation. Secondary outcomes included the risk of adverse events. Statistical analysis was performed using R software. Results. We analyzed data from 10 studies involving 1666 patients, addressing infections such as pneumonia, wound infections, cellulitis, major abscesses, lower extremity ulcers, erysipelas, cystitis, and bone or joint infections. The analysis showed a 90% (1138 of 1264 patients; 95% CI: 88 - 91) clinical success rate at the end of treatment and 84% (1288 of 1534 patients; 95% CI: 82 - 86) success rate at post-treatment evaluation. Adverse events occurred in 45% (747 of 1662; 95% CI: 32 - 59), with 18% [181 of 1008; 95% CI: 13 - 24] experiencing gastrointestinal issues. The mortality rate was 0% (0,8%) (13 patients; 95% CI: 0 - 1). Conclusions. Omadacycline is a promising option for treating community-acquired infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.